Press release
Biosimilars Market Prognosticated For a Ravishing Growth at 26% CAGR by 2023 | by Amgen Inc., Astra Zeneca, Biocon Ltd., Celltrion, Dr. Reddy’s Laboratories Ltd., etc
The Global Biosimilars Market Report is Recently Published By Market Research Future Firm. Report include market exclusive analysis on the basis of industry size, recent trends and demand supply. Market analysis is available on MarketResearchFuture.com uniquely by 80+ pages information, 30+ tables and 30+ figures exclusively.The segmentation Global Biosimilars Market is on the basis of application, manufacturing, product, and region. The application based segmentation segments the market into blood-related disorders, immunity-related diseases, oncology, and other. Based on manufacturing, the market has contract manufacturing and in-house manufacturing. As per segmentation based on product, the market has been segmented into recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others. Recombinant glycosylated proteins have been further segmented into Monoclonal antibody (mAb) and EPO. Recombinant non-glycosylated proteins have been further segmented into growth hormones, insulin, and other.
Get Sample PDF Illustration @ https://www.marketresearchfuture.com/sample_request/1329
Biosimilars Market - Overview
A Biosimilar is described as a biological, medical product which is an identical copy of the original medical product. Market Research Future (MRFR) has published and released a research report about the global biosimilars market that predicts massive enlargement for this market with 26% CAGR during the forecast period between 2016 and 2023. In terms of cash, the market has been anticipated to rise to the US $ 16.97 bn.
Analyzing the market structure, this report estimates the future growth potential of the market. It observes the strategies of the key players in the market and follows the competitive developments like joint ventures, new product developments, mergers and acquisitions, research and developments (R & D) in the market. This report also covers insights on the major countries/regions in which this industry is flourishing, along with the list and description of untapped regions which could be the potential markets in the future.
The key factors aiding the growth of the global biosimilars market include clinical trial activities for biosimilars, increasing demand for the cheap medical products, increasing incident of different diseases, and strategic collaborations resulting in enhanced productivity. However, lack of awareness and physician skepticism are the major restraining factor regarding market growth.
Key Players for Global Biosimilars Market
The key players in the global biosimilars market include Accord Healthcare (UK), Amgen Inc. (USA), Astra Zeneca (UK), Biocon Ltd. (India), Celltrion, Inc. (South Korea), Dr. Reddy’s Laboratories Ltd. (India), Eli Lilly (USA), F. Hoffmann-La Roche Ltd. (Switzerland), Novartis (Switzerland), Pfizer Inc. (USA), Samsung Bioepis (South Korea), Sandoz International GmbH (Germany), and Teva Pharmaceuticals Industries Ltd. (Israel).
Latest Industry News
Mundipharma, a network of independent pharma companies, has acquired Spanish biosimilars development company Cinfa Biotech. The deal gives Mundipharma, access to a biosimilar to Amgen’s Neulasta (pegfilgrastim). 10 OCT 2018
The new white paper issued by the Association of European Cancer Leagues, a nonprofit, pan-European organization of national and regional cancer societies, has called for the greater use of biosimilars as a means to increase patient access to cancer treatment, and reduce costs. 10 OCT 2018
Segments for Global Biosimilars Market
Get Prime Discount on Report @ https://www.marketresearchfuture.com/check-discount/1329
Some Brief Table of Contents of Report
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
TOC Continued…
Browse Complete report @ https://www.marketresearchfuture.com/reports/biosimilars-market-1329
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Hadapsar, Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilars Market Prognosticated For a Ravishing Growth at 26% CAGR by 2023 | by Amgen Inc., Astra Zeneca, Biocon Ltd., Celltrion, Dr. Reddy’s Laboratories Ltd., etc here
News-ID: 1407038 • Views: …
More Releases from Market Research Future

9-Decanoic Acid Methyl Ester Market Poised for Strong 6.59% CAGR Growth Through …
The 9-decanoic acid methyl ester market is a growing sector driven by the increasing demand for bio-based and sustainable chemical products across various industries. With its unique properties, it finds application in flavors and fragrances, pharmaceuticals, personal care, and as a chemical intermediate. The market is projected to expand significantly in the coming years.
Market Overview and Size
The global 9-decanoic acid methyl ester market was valued at USD 230.0 million in…

Washable Marker Market Poised for 3.54% CAGR Growth During 2024-2032
The washable marker market is a dynamic and growing segment within the broader stationery and art supplies industry. Driven by a blend of consumer demands for safety, convenience, and sustainability, the market is experiencing consistent expansion, particularly within the education and home-use sectors. While faced with some challenges, the industry's future looks promising, propelled by product innovation and evolving consumer trends.
Get Sample @ https://www.marketresearchfuture.com/sample_request/41217
Market Size and Growth
The global washable…

Phone Car Mounts Market to Reach USD 7.37 Billion by 2034, Growing at 6.47% CAGR
The phone car mounts market, a critical sub-segment of the broader automotive accessories industry, is experiencing robust growth driven by a convergence of technological advancements, evolving consumer behavior, and increasingly stringent road safety regulations. As smartphones become indispensable for navigation, communication, and in-car entertainment, the demand for secure and convenient hands-free solutions continues to escalate. The global phone car mounts market was valued at USD 3.93 billion in 2024 and…

Intravenous (IV) Solution Market Set to Grow to USD 26.60 Billion at 7.70% CAGR …
Market Overview:
The Intravenous (IV) Solution Market is estimated to be valued at USD 13.9 billion in 2023 and is projected to reach USD 26.60 billion by 2032, expanding at a compound annual growth rate (CAGR) of 7.70% from 2024 to 2031. The market growth is attributed to the rising prevalence of chronic diseases, growing hospitalization rates, and increasing surgical procedures that require IV fluid administration. Intravenous solutions are critical…
More Releases for Biosimilar
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get…
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02…
Infliximab Biosimilar Insight, 2023 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2023" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…